Our technology

Our technology

Our patented gene transfer technology

Our unique patented gene transfer technology allows the development of numerous drug candidates for a range of different pharmaceutical applications. Our technology can be used to develop drugs for the treatment of conditions such as cancer and a range of infectious diseases. Our most advanced product is a DNA vaccine FIT-06 that we develop for treating HIV. 

Stronger and more
persistent gene expression

The engineered E2 element of the GTU® vector allows for more persistent expression of genes in both non-dividing and dividing cells. It is non-viral, which means that there is neither risk of vector replication nor integration of unwanted DNA into the patient's genome. GTU has been tested in 10 clinical trials to date. It has been found to be safe and well tolerated according to several national regulatory authorities.

Play video presentation

Overcoming the inherent weakness
of tissue-specific promoters

Thanks to our engineered E2 element we can overcome the inherent weakness of tissue-specific promoters, enabling better expression of genes where needed. We have vectors available for a range of tissues.

Next-generation vector for gene therapies

Our new gtGTU(R) technology enables the expression of several new types of strong and persistent genes. Expression of, for instance a therapeutic antibody, can be sustained for up to months, challenging current therapeutic modalities.

Download technology overview PDF

Antibiotic-free

We are concerned with the growing global problem of antibiotic resistance, and have developed a proprietary technology that allows completely antibiotic-free production of therapeutics.

Download technology overview PDF

* Not disclosed

List of publications

Electroporation as a vaccine delivery system and a natural adjuvant to intradermal
administration of plasmid DNA in macaques.

Todorova B, Adam L, Culina S, Boisgard R, Martinon F, Cosma A, Ustav M, Kortulewski T, Le Grand R, Chapon C.

Sci Rep. 2017 Jun 23;7(1):4122

Read more

Electroporation as a vaccine delivery system and a natural adjuvant to intradermal
administration of plasmid DNA in macaques.

Todorova B, Adam L, Culina S, Boisgard R, Martinon F, Cosma A, Ustav M, Kortulewski T, Le Grand R, Chapon C.

Sci Rep. 2017 Jun 23;7(1):4122

Read more

Electroporation as a vaccine delivery system and a natural adjuvant to intradermal
administration of plasmid DNA in macaques.

Todorova B, Adam L, Culina S, Boisgard R, Martinon F, Cosma A, Ustav M, Kortulewski T, Le Grand R, Chapon C.

Sci Rep. 2017 Jun 23;7(1):4122

Read more

Electroporation as a vaccine delivery system and a natural adjuvant to intradermal
administration of plasmid DNA in macaques.

Todorova B, Adam L, Culina S, Boisgard R, Martinon F, Cosma A, Ustav M, Kortulewski T, Le Grand R, Chapon C.

Sci Rep. 2017 Jun 23;7(1):4122

Read more

List of publications:

  • Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial. Haidari G, Cope A, Miller A, Venables S, Yan C, Ridgers H, Reijonen K, Hannaman D, Spentzou A, Hayes P, Bouliotis G, Vogt A, Joseph S, Combadiere B7, McCormack S, Shattock RJ. Sci Rep. 2017 Oct 12;7(1):13011 .
    Read more here.
  • Electroporation as a vaccine delivery system and a natural adjuvant to intradermal administration of plasmid DNA in macaques. Todorova B, Adam L, Culina S, Boisgard R, Martinon F, Cosma A, Ustav M, Kortulewski T, Le Grand R, Chapon C. Sci Rep. 2017 Jun 23;7(1):4122
    Read more here.
  • Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection. Herasimtschuk A, Downey J, Nelson M, Moyle G, Mandalia S, Sikut R, Adojaan M, Stanescu I, Gotch F, Imami N. Vaccine. 2014 Dec 5;32(51):7005-7013
    Read more here.